Company profile
Bristol-Myers Squibb Company
NYSE: BMY · Healthcare · Drug Manufacturers - General
#15 of 1,418 Healthcare companies by revenue41st-percentile growth
EA Score
85AFH 82DQ 98GM 59SS 99
v0.1 · 65/100 weight · provisional
↑ listing tenure, market scale · ↓ balance-sheet leverage, revenue growth (YoY)
Methodology →Revenue TTM
$48.5B
Rev growth YoY (TTM)
+1.8%
Net income (FY)
$7.1B
Employees
32,500
as of 2026-09-04
Market cap
$139.1B
as of 2026-09-04
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$48.2B$48.2B2025
Net income$7.1B$7.1B2025
Total assets$90.0B$90.0B2025
Liabilities$71.5B$71.5B2025
Equity$18.5B$18.5B2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Eliquis30%
Opdivo21%
Orencia8%
Revlimid6%
Yervoy6%
Pomalyst/Imnovid6%
By geography
UNITED STATES97%
Other Region3%
The read
What is Bristol-Myers Squibb Company’s revenue?
Bristol-Myers Squibb Company booked $48.2B in FY2025 revenue, contracting 0.2% year over year — about the middle of the pack among Healthcare companies we track, at a 14.6% net margin.
Peers · Healthcare
Merck & Co., Inc.84B+Pfizer Inc.76B+AbbVie Inc.81B+Molina Healthcare, Inc.83B+Thermo Fisher Scientific Inc.86AAbbott Laboratories87ANeighbors
Mercer →Key facts
CEOChristopher Boerner
SectorHealthcare
IndustryDrug Manufacturers - General
HeadquartersPrinceton, NJ
ExchangeNYSE: BMY
Employees32,500
IPO date1972-06-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.